Risk-reducing salpingo-oophorectomy in BRCA mutation carriers:: Role of serial sectioning in the detection of occult malignancy

被引:260
作者
Powell, CB
Kenley, E
Chen, LM
Crawford, B
McLennan, J
Zaloudek, C
Komaromy, M
Beattie, M
Ziegler, J
机构
[1] Univ Calif San Francisco, Ctr Comprehens Canc, Gynecol Oncol Program, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Comprehens Canc, Canc Risk Program, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2005.04.109
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Women who carry deleterious mutations of BRCA1 or BRCA2 genes have up to a 54% lifetime risk of developing ovarian cancer. After childbearing, women at high risk increasingly choose bilateral risk-reducing salpingo-oophorectomy (RRSO). Two recent studies of BRCA mutation carriers reported occult malignancy in 2.5% of women undergoing RRSO. This study aimed to increase this detection rate using a protocol. Methods In 1996, the University of California San Francisco Gynecologic Oncology Program instituted a surgical-pathologic RRSO protocol that was composed of complete removal and serial sectioning of both ovaries and fallopian tubes, peritoneal and omental biopsies, and collection of peritoneal washings for cytology. We report the pathologic findings in 67 BRCA mutation carriers according to. the degree of adherence to this protocol. Results Of the 67 procedures, the protocol was followed completely or partially in 41 (61%). Seven occult malignancies were discovered, four in the fallopian tube and three in the ovaries. Six of these were microscopic, and all seven (17%) were found in specimens from complete or partial protocol procedures as opposed to standard procedures (P = .026). Other variables such as age, parity, BRCA1 or BRCA2 mutation, or type of surgery did not alter the strong effect of protocol procedure on the cancer detection rate. Conclusion A rigorous operative and pathologic protocol for RRSO increases the detection rate of occult ovarian malignancy in BRCA mutation carriers nearly seven-fold. If confirmed, this finding will alter postoperative management because additional staging, chemotherapy, and follow-up may be necessary in affected women.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 18 条
[1]   Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or-2 mutations - Implications for gross examination, cytology, and clinical follow-up [J].
Agoff, SN ;
Mendelin, JE ;
Grieco, VS ;
Garcia, RL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (02) :171-178
[2]  
[Anonymous], 1995, JAMA, V273, P491
[3]  
[Anonymous], 2003, PATHOLOGY GENETICS T
[4]   Occult carcinoma in prophylactic oophorectomy specimens - Prevalence and association with BRCA germline mutation status [J].
Colgan, TJ ;
Murphy, J ;
Cole, DEC ;
Narod, S ;
Rosen, B .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (10) :1283-1289
[5]   Risk management in BRCA1 and BRCA2 mutation carriers:: Lessons learned, challenges posed [J].
DeMichele, A ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1164-1166
[6]   Clues to the pathogenesis of fallopian tube carcinoma: A morphological and immunohistochemical case control study [J].
Demopoulos, RI ;
Aronov, R ;
Mesia, A .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2001, 20 (02) :128-132
[7]   Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations [J].
Haber, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) :1660-1662
[8]   Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. [J].
Kauff, ND ;
Satagopan, JM ;
Robson, ME ;
Scheuer, L ;
Hensley, M ;
Hudis, CA ;
Ellis, NA ;
Boyd, J ;
Borgen, PI ;
Barakat, RR ;
Norton, L ;
Offit, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) :1609-1615
[9]   Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 [J].
King, MC ;
Marks, JH ;
Mandell, JB .
SCIENCE, 2003, 302 (5645) :643-646
[10]   Pathologic findings in prophylactic oophorectomy specimens in high-risk women [J].
Leeper, K ;
Garcia, R ;
Swisher, E ;
Goff, B ;
Greer, B ;
Paley, P .
GYNECOLOGIC ONCOLOGY, 2002, 87 (01) :52-56